A detailed history of Rock Springs Capital Management LP transactions in Mereo Biopharma Group PLC stock. As of the latest transaction made, Rock Springs Capital Management LP holds 9,283,492 shares of MREO stock, worth $38.1 Million. This represents 1.04% of its overall portfolio holdings.

Number of Shares
9,283,492
Previous 8,142,109 14.02%
Holding current value
$38.1 Million
Previous $26.9 Million 24.39%
% of portfolio
1.04%
Previous 0.7%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$2.58 - $4.25 $2.94 Million - $4.85 Million
1,141,383 Added 14.02%
9,283,492 $33.4 Million
Q1 2024

May 15, 2024

BUY
$2.3 - $4.05 $363,993 - $640,944
158,258 Added 1.98%
8,142,109 $26.9 Million
Q4 2023

Feb 14, 2024

BUY
$1.19 - $2.42 $365,770 - $743,835
307,370 Added 4.0%
7,983,851 $18.4 Million
Q3 2023

Nov 14, 2023

BUY
$1.15 - $1.67 $729,203 - $1.06 Million
634,090 Added 9.0%
7,676,481 $9.9 Million
Q2 2023

Aug 14, 2023

BUY
$0.79 - $1.43 $630,020 - $1.14 Million
797,494 Added 12.77%
7,042,391 $9.3 Million
Q3 2022

Nov 14, 2022

BUY
$0.82 - $1.73 $11,990 - $25,296
14,622 Added 0.23%
6,244,897 $5.38 Million
Q2 2022

Aug 15, 2022

BUY
$0.33 - $1.69 $51,259 - $262,511
155,332 Added 2.56%
6,230,275 $6.98 Million
Q1 2022

May 16, 2022

BUY
$1.04 - $1.7 $508,894 - $831,847
489,322 Added 8.76%
6,074,943 $6.8 Million
Q4 2021

Feb 14, 2022

BUY
$1.51 - $2.59 $1.14 Million - $1.95 Million
752,643 Added 15.57%
5,585,621 $8.94 Million
Q3 2021

Nov 15, 2021

BUY
$2.2 - $3.17 $638,459 - $919,962
290,209 Added 6.39%
4,832,978 $11.7 Million
Q2 2021

Aug 16, 2021

BUY
$2.94 - $4.08 $140,826 - $195,432
47,900 Added 1.07%
4,542,769 $14.4 Million
Q1 2021

May 17, 2021

BUY
$2.6 - $4.43 $11.7 Million - $19.9 Million
4,494,869 New
4,494,869 $15.1 Million

Others Institutions Holding MREO

About Mereo Biopharma Group plc


  • Ticker MREO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 124,986,000
  • Market Cap $512M
  • Description
  • Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom and internationally. Its lead product candidate, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the tr...
More about MREO
Track This Portfolio

Track Rock Springs Capital Management LP Portfolio

Follow Rock Springs Capital Management LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rock Springs Capital Management LP, based on Form 13F filings with the SEC.

News

Stay updated on Rock Springs Capital Management LP with notifications on news.